AstraZeneca's AZD5462 (Compound I, an amino acid derivative per A61K 31/196) in specific dosing regimens for treating heart failure (A61P 9/04).

Patentradars sammanfattning

This PCT application (WO 2025/036918 A1) from AstraZeneca AB discloses dosing regimens, treatment methods, and pharmaceutical compositions centered on AZD5462 (Compound I) or its pharmaceutically acceptable salts for the treatment of heart failure. The compound falls under IPC class A61K 31/196, indicating a carboxylic acid-bearing small molecule (likely an amino acid or related derivative), directed at a cardiotonic/heart failure indication (A61P 9/04). The application claims priority from two US provisional filings (August 2023 and February 2024), suggesting iterative clinical or preclinical refinement of dosing strategies over that period.

AI-genererad och redaktionellt processad.